The Therapeutic Products Directorate (TPD), the Biologic and Radiopharmaceutical Drugs Directorate (BRDD), and the Natural and Non-Prescription Health Products Directorate (NNHPD) have released their Drug Submission Performance Annual Reports for the Fiscal Year 2020-2021 (April 1, 2020 to March 31, 2021). The reports contain information regarding pharmaceutical, biologic and radiopharmaceutical drug submission review activity including average approval times.
The TPD, BRDD and NNHPD 2020-2021 reports also highlight significant events that occurred during the spring of 2020 such as the COVID-19 pandemic, and includes a section on applications under: (1) the Interim Order Respecting Clinical Trials for Medical Devices and Drugs Relating to COVID-19 (see our article here), and (2) the Interim Order Respecting the Importation, Sale and Advertising of Drugs for Use in Relation to COVID-19 (see article here).
Should you have any questions, please do not hesitate to contact a member of the Life Sciences Regulatory & Compliance Group.
The preceding is intended as a timely update on Canadian intellectual property and technology law. The content is informational only and does not constitute legal or professional advice. To obtain such advice, please communicate with our offices directly.
Related Publications & Articles
-
Health Canada and the Competition Bureau commit to information sharing to combat false, misleading or deceptive health claims
On March 7, 2024, Health Canada published a Memorandum of Understanding (MOU) with the Competition Bureau (together, Participants) to advance their mutual interests and develop a framework of cooperat...Read More -
Update on biosimilars in Canada – March 2024
In this article, we provide a further update on developments regarding biosimilars in Canada (approvals, pending submissions, litigation, regulatory, and market access).Read More -
Generic Submissions Under Review list will identify generic filers
On February 23, 2024, Health Canada announced that it will expand the information available on the Generic Submissions Under Review (GSUR) list.Read More